10x Genomics, Inc.
Business Overview: 10x Genomics, Inc. (NASDAQ: TXG)
Executive Summary
10x Genomics, Inc. develops and sells instruments, consumables, and software that let researchers analyze biological samples at single-cell and spatial resolution — seeing which genes are active in individual cells and where in a tissue sample that activity is happening, rather than only measuring an averaged signal across a bulk sample. Headquartered in Pleasanton, California, 10x Genomics sells primarily to academic, government, biopharmaceutical, and translational research labs worldwide.
10x Genomics matters because single-cell and spatial biology have become foundational tools in modern life-science research — used in drug discovery, immuno-oncology, and basic biology — and 10x built an early, broad instrument and consumables franchise around its Chromium (single-cell) and Visium/Xenium (spatial) platforms that put it among the category's most recognized names.
1. Core Business Model & How They Work
10x Genomics follows a classic "razor and blades" model: it sells capital instruments (Chromium Controller/X, Xenium Analyzer) at a relatively modest price, then earns recurring, higher-margin revenue from the proprietary consumables (reagent kits, chips, slides) that every sample run requires.
[ Instrument Sale (Chromium / Xenium) ] ➡️ [ Recurring Consumables Revenue Per Sample ] ➡️ [ Software/Analysis Tools ] ➡️ [ Published Research Drives More Adoption ]Because each instrument installed base generates an ongoing consumables revenue stream, and because consumables carry higher gross margin than the instruments themselves, 10x's growth is a function both of placing new instruments and of driving consumable "pull-through" utilization on its existing installed base.
2. Business Segments
┌───────────────────────────────┐
│ 10x Genomics │
└──────────────┬──────────────────┘
│
┌────────────┼─────────────────┐
▼ ▼ ▼
┌─────────┐ ┌──────────┐ ┌──────────────┐
│Chromium │ │ Visium / │ │ Software │
│(Single- │ │ Xenium │ │ & Analysis │
│ Cell) │ │(Spatial) │ │ │
└─────────┘ └──────────┘ └──────────────┘Chromium (Single-Cell)
The company's original and still largest platform, enabling single-cell gene expression, immune profiling, and multiomic analysis.
Visium / Xenium (Spatial)
Spatial biology platforms that map gene or protein expression to specific physical locations within a tissue section, a newer and faster-growing category for the company.
Software & Analysis
Bioinformatics software that helps customers process and interpret the large single-cell and spatial datasets generated by 10x instruments.
3. Product Portfolio
| Product | Category | Purpose | Why It Matters |
|---|---|---|---|
| Chromium Controller / Chromium X | Single-cell instrument | Partitions individual cells for single-cell sequencing prep | Installed base anchor driving recurring consumables |
| Chromium Single Cell Kits | Consumables | Reagents/chips for single-cell gene expression and immune profiling | Recurring, higher-margin revenue per sample |
| Xenium Analyzer | Spatial instrument | In-situ spatial gene/protein mapping within intact tissue | Newer, faster-growing spatial biology platform |
| Visium | Spatial consumables | Slide-based spatial transcriptomics | Complements Xenium for different spatial-resolution needs |
4. Competitive Landscape
SINGLE-CELL + SPATIAL BREADTH
High │
│ [10x GENOMICS]
│
│ [Parse Biosciences] [Illumina]
│ [Scale Bio] [NanoString/Bruker]
│ [Vizgen]
Low │
└────────────────────────────────────►
Low INSTALLED-BASE SCALE High10x Genomics competes in single-cell analysis against Parse Biosciences and Scale Biosciences, and in spatial biology against NanoString (now part of Bruker), Vizgen, and large diversified life-science tool makers like Illumina and Thermo Fisher that have moved into adjacent genomics workflows.
5. Strategic Strengths & Risks
Strengths:
- Large, long-standing installed base of Chromium instruments generates recurring consumables revenue.
- Improving profitability metrics: gross margin rose to 69% in FY2025 from 68% in FY2024, and cash plus marketable securities grew to $523.4 million (FY2025) from roughly $393.4 million (FY2024), strengthening the balance sheet.
- Broad platform spanning both single-cell and spatial biology lets the company sell into adjacent workflows within the same customer labs.
Risks:
- Customer concentration in academic/government research, which is sensitive to funding cycles (e.g., U.S. federal research budget pressure).
- Intensifying spatial-biology competition from NanoString/Bruker, Vizgen, and large diversified players entering the category.
- Capital-equipment sales cyclicality, since large lab capex purchases can be deferred in tighter funding environments.
- History of patent litigation in the single-cell and spatial sequencing space, which can be costly and create competitive uncertainty.
6. Financial Overview
| Metric | 10x Genomics (TXG) | Strategic Context |
|---|---|---|
| Gross margin (FY2025) | 69% | Up from 68% in FY2024 — consumables mix and manufacturing efficiency improving |
| Cash + marketable securities (FY2025) | $523.4M | Up from ~$393.4M in FY2024 — meaningfully strengthened liquidity position |
| Revenue mix | Instruments + recurring consumables + software | Consumables pull-through on the installed base is the key long-term growth driver |
7. Summary Conclusion
10x Genomics' business is built on placing single-cell and spatial biology instruments into research labs and then earning durable, higher-margin consumables revenue every time those instruments are used — a model whose health is best read through gross margin trends and cash position rather than instrument unit sales alone. The improvement in both gross margin and liquidity in FY2025 suggests the installed base and consumables pull-through are maturing in the company's favor, but continued intensifying competition in spatial biology and the company's exposure to academic and government research funding cycles remain the key variables to watch.